Vaccinex, Inc.
VCNX · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $213 | $52 | $232 | $104 |
| % Growth | 309.6% | -77.6% | 123.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $27 |
| Gross Profit | $213 | $52 | $232 | $77 |
| % Margin | 100% | 100% | 100% | 74% |
| R&D Expenses | $2,133 | $3,165 | $3,864 | $3,383 |
| G&A Expenses | $1,467 | $1,439 | $2,090 | $1,795 |
| SG&A Expenses | $1,467 | $1,439 | $2,090 | $1,795 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$27 |
| Operating Expenses | $3,600 | $4,604 | $5,954 | $5,151 |
| Operating Income | -$3,387 | -$4,552 | -$5,722 | -$5,074 |
| % Margin | -1,590.1% | -8,753.8% | -2,466.4% | -4,878.8% |
| Other Income/Exp. Net | $13 | -$1,180 | $91 | $1,177 |
| Pre-Tax Income | -$3,374 | -$5,732 | -$5,631 | -$3,897 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,374 | -$5,732 | -$5,631 | -$3,897 |
| % Margin | -1,584% | -11,023.1% | -2,427.2% | -3,747.1% |
| EPS | -1.61 | -2.83 | -3.1 | -2.94 |
| % Growth | 43.1% | 8.7% | -5.4% | – |
| EPS Diluted | -1.61 | -2.83 | -3.1 | -2.94 |
| Weighted Avg Shares Out | 2,099 | 2,027 | 1,818 | 1,327 |
| Weighted Avg Shares Out Dil | 2,099 | 2,027 | 1,818 | 1,327 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $0 | $0 | $28 |
| Depreciation & Amortization | $17 | $24 | $25 | $27 |
| EBITDA | -$3,355 | -$5,708 | -$5,606 | -$3,842 |
| % Margin | -1,575.1% | -10,976.9% | -2,416.4% | -3,694.2% |